|
Diaz LS, Navalon CI, Espin RG, Prado IN, Redondo LR. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2023 Aug-Sep;46(7):504-511. doi: 10.1016/j.gastrohep.2022.10.019. Epub 2022 Nov 15. English, Spanish. PubMed PMID: 36400260.
AÑO: 2023; IF: 2.2
|
36400260
|
Serrano-Diaz L, Iniesta-Navalon C, Gomez-Espin R, Nicolas-de Prado I, Bernal-Morell E, Rentero-Redondo L. Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach. Rev Esp Enferm Dig. 2023 Aug;115(8):435-443. doi: 10.17235/reed.2022.8781/2022. PubMed PMID: 36562529.
AÑO: 2023; IF: 2.7
|
|
Iniesta Navalon C, Rios-Saorin M, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. Rev Esp Enferm Dig. 2024 Dec 4. doi: 10.17235/reed.2024.10521/2024. Online ahead of print. PubMed PMID: 39629805.
AÑO: 2024; IF: 2.7
|